Avian-derived monoclonal antibody therapeutic - Pharma Foods International/Mitsubishi Tanabe Pharma
Latest Information Update: 28 Feb 2025
At a glance
- Originator Pharma Foods International
- Developer Mitsubishi Tanabe Pharma Corporation; Pharma Foods International
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Inflammation in Japan (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in Japan (Parenteral)
- 28 Jun 2024 Pharma Foods International submits a Clinical Trial Notification to the Pharmaceutical and Medical Devices Agency (PMDA) for a clinical trial in Autoimmune disorders, prior to June 2024